R.B. Shahi MSc, B. Caljon , S. De Brakeleer PhD, L. Decoster MD, PhD, C. Fontaine MD, L. Vanacker MD, M. Vanhoeij , I. Pauwels , M-L. Bonduelle , S. Van Dooren PhD, D. Croes , E. Teugels PhD, J. De Grève MD, PhD
J. De Grève MD, PhD, L. Decoster MD, PhD, R.B. Shahi MSc, C. Fontaine MD, L. Vanacker MD, I. Pauwels , E. Denayer MD, PhD, S. De Brakeleer PhD, E. Teugels PhD
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifically and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the first to therapeutically exploit mutant recessive cancer genes. In this review we discuss the discovery of this treatment, the preclinical and clinical studies, as well as some future perspectives.